Helicobacter pylori infection and related gastrointestinal diseases

Journal of Clinical Gastroenterology

Volumn 41, Issue 6, 2007, Pages 548-558

  Makola, Diklar ^a   Peura, David A ^a   Crowe, Sheila E ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Dyspepsia; Gastritis; GERD; Helicobacter pylori; Peptic ulcer disease; Stomach cancer

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ARTHRITIS; BACTERIAL GENOME; BACTERIAL VIRULENCE; CANCER RISK; CARCINOGENESIS; CHRONIC GASTRITIS; CLINICAL TRIAL; DIET; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DUODENUM ULCER; DYSPEPSIA; ENVIRONMENTAL FACTOR; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEREDITY; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PATHOGENESIS; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RECURRENT DISEASE; REFLUX ESOPHAGITIS; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; STOMACH ULCER; STROKE;

ANIMALS; COMORBIDITY; DUODENAL ULCER; DYSPEPSIA; ESOPHAGITIS, PEPTIC; GASTRITIS; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; PEPTIC ULCER; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 34250703132     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318030e3c3     Document Type: Review

References (72)

1. Marshall BJ, McGechie DB, Rogers PA, et al. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust. 1985;142:439-444.
2. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175-1186.
3. Marshall BJ, Windsor HM. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am. 2005;89:313-344.
4. Pezzi JS, Shiau YF. Helicobacter pylori and gastrointestinal disease. Am Fam Physician. 1995;52:1717-1724, 1729.
5. Tsai CJ, Perry S, Sanchez L, et al. Helicobacter pylori infection in different generations of Hispanics in the San Francisco Bay Area. Am J Epidemiol. 2005;162:351-357.
6. Kivi M, Tindberg Y. Helicobacter pylori occurrence and transmission: a family affair? Scand J Infect Dis. 2006;38:407-417.
7. Del Valle J, Chey W, Scheiman J. Acid Peptic Disorders. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.
8. Aoyama N, Shinoda Y, Matsushima Y, et al. Helicobacter pylori-negative peptic ulcer in Japan: which contributes most to peptic ulcer development, Helicobacter pylori, NSAIDS or stress? J Gastroenterol 2000;35(suppl 12):33-37.
9. Weyermann M, Adler G, Brenner H, et al. The mother as source of Helicobacter pylori infection. Epidemiology. 2006;17:332-334.
10. Rodrigues MN, Queiroz DM, Braga AB, et al. History of breastfeeding and Helicobacter pylori infection in children: results of a community-based study from northeastern Brazil. Trans R Soc Trop Med Hyg. 2006;100:470-475.
11. Kivi M, Johansson AL, Reilly M, et al. Helicobacter pylori status in family members as risk factors for infection in children. Epidemiol Infect. 2005;133:645-652.
12. Brenner H, Weyermann M, Rothenbacher D. Clustering of Helicobacter pylori infection in couples: differences between high- and low-prevalence population groups. Ann Epidemiol. 2006;16:516-520.
13. Parsonnet J, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA. 1999;282:2240-2245.
14. Ferguson DA Jr, Li C, Patel NR, et al. Isolation of Helicobacter pylori from saliva. J Clin Microbiol. 1993;31:2802-2804.
15. Krajden S, Fuksa M, Anderson J, et al. Examination of human stomach biopsies, saliva, and dental plaque for Campylobacter pylori. J Clin Microbiol. 1989;27:1397-1398.
16. Mapstone NP, Lynch DA, Lewis FA, et al. Identification of Helicobacter pylori DNA in the mouths and stomachs of patients with gastritis using PCR. J Clin Pathol. 1993;46:540-543.
17. Malaty HM, Evans DJ Jr, Abramovitch K, et al. Helicobacter pylori infection in dental workers: a seroepidemiology study. Am J Gastroenterol. 1992;87:1728-1731.
18. Perez-Perez GI, Witkin SS, Decker MD, et al. Seroprevalence of Helicobacter pylori infection in couples. J Clin Microbiol. 1991;29:642-644.
19. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol. 1993;88:505-509.
20. Helicobacter pylori and peptic ulcer disease; economics of peptic ulcer disease and H. pylori infection [Centers for Disease Control and Prevention Web site]. October, 1998. Available at: http://www.cdc.gov/ulcer/ economic.htm. Accessed September 24, 2006.
21. Gaby AR. Helicobacter pylori eradication: are there alternatives to antibiotics? Altern Med Rev. 2001;6:355-366.
22. Xia B, Xia HH, Ma CW, et al. Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong. Aliment Pharmacol Ther. 2005;22:243-249.
23. Wong SN, Sollano JD, Chan MM, et al. Changing trends in peptic ulcer prevalence in a tertiary care setting in the Philippines: a seven-year study. J Gastroenterol Hepatol. 2005;20:628-632.
24. Perez-Aisa MA, Del Pino D, Siles M, et al. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2005;21:65-72.
25. Ciociola AA, McSorley DJ, Turner K, et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol. 1999;94:1834-1840.
26. Leung W, Ng E, Sung J. Tumors of the Stomach. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.
27. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053.
28. Pandolfino JE, Howden CW, Kahrilas PJ. H. pylori and GERD: is less more? Am J Gastroenterol. 2004;99:1222-1225.
29. Labenz J, Blum AL, Bayerdorffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997;112:1442-1447.
30. Megraud F. A humble bacterium sweeps this year's Nobel Prize. Cell. 2005;123:975-976.
31. Calam J, Gibbons A, Healey ZV, et al. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology. 1997;113:S43-S49.
32. Beales IL, Calam J. The histamine H3 receptor agonist N alphamethylhistamine produced by Helicobacter pylori does not alter somatostatin release from cultured rabbit fundic D-cells. Gut. 1998;43:176-181.
33. Del Valle J, Todisco A. Gastric Secretion. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.
34. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology. 2006;130:188-206.
35. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19:449-490.
36. Hunt RH, Bazzoli F. Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther. 2004;19 (suppl 1):9-16.
37. Hawkey CJ. Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance. Aliment Pharmacol Ther. 1999;13:695-702.
38. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14-22.
39. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967-973.
40. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002;359:9-13.
41. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet. 1998;352:1016-1021.
42. Malfertheiner P, Peitz U. The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia. Gut. 2005;54(suppl 1):i13-i20.
43. Malfertheiner P, Dent J, Zeijlon L, et al. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - results from a randomized trial programme. Aliment Pharmacol Ther. 2002;16:1431-1442.
44. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol. 2002;97:2992-2997.
45. Tsukada K, Katoh H, Miyazaki T, et al. Factors associated with the development of reflux esophagitis after Helicobacter pylori eradication. Dig Dis Sci. 2006;51:539-542.
46. Pilotto A, Perri F, Leandro G, et al. Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study. Gerontology. 2006;52:99-106.
47. Inoue H, Imoto I, Taguchi Y, et al. Reflux esophagitis after eradication of Helicobacter pylori is associated with the degree of hiatal hernia. Scand J Gastroenterol. 2004;39:1061-1065.
48. Ishiki K, Mizuno M, Take S, et al. Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease. Clin Gastroenterol Hepatol. 2004;2:474-479.
49. Rokkas T, Ladas SD, Triantafyllou K, et al. The association between CagA status and the development of esophagitis after the eradication of Helicobacter pylori. Am J Med. 2001;110:703-707.
50. Kawanishi M. Development of reflux esophagitis following Helicobacter pylori eradication. J Gastroenterol. 2005;40:1024-1028.
51. Chey WD, Moayyedi P. Review article: uninvestigated dyspepsia and non-ulcer dyspepsia-the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy. Aliment Pharmacol Ther. 2004;19(suppl 1):1-8.
52. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ. 2000;321:659-664.
53. Infection with Helicobacter pylori (group 1) [International Agency for Research on Cancer Web site]. August 26, 1997. Available at http://monographs.iarc.fr/ENG/Monographs/vol61/volume61.pdf. Accessed September 24, 2006.
54. Zhang C, Yamada N, Wu YL, et al. Helicobacter pylori infection, glandular atrophy and intestinal metaplasia in superficial gastritis, gastric erosion, erosive gastritis, gastric ulcer and early gastric cancer. World J Gastroenterol. 2005;11:791-796.
55. Genta RM, Rugge M. Gastric precancerous lesions: heading for an international consensus. Gut. 1999;45(suppl 1):5-8.
56. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735-6740.
57. Zivny J, Wang TC, Yantiss R, et al. Role of therapy or monitoring in preventing progression to gastric cancer. J Clin Gastroenterol. 2003;36:S50-S60.
58. Huang JQ, Hunt RH. Review article: Helicobacter pylori and gastric cancer - the clinicians'point of view. Aliment Pharmacol Ther. 2000;14(suppl 3):48-54.
59. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. Science. 2004;306:1568-1571.
60. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784-789.
61. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187-194.
62. Figueiredo C, Machado JC, Pharoah P, et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst. 2002;94:1680-1687.
63. Lu H, Hsu PI, Graham DY, et al. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology. 2005;128:833-848.
64. Huang JQ, Zheng GF, Sumanac K, et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2003;125:1636-1644.
65. El-Omar EM. The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut. 2001;48:743-747.
66. El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003;124:1193-1201.
67. Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000;119:7-14.
68. Puspok A, Raderer M, Chott A, et al. Endoscopic ultrasound in the follow up and response assessment of patients with primary gastric lymphoma. Gut. 2002;51:691-694.
69. Stolte M, Bayerdorffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut. 2002;50(suppl 3):19-24.
70. Fischbach W, Goebeler-Kolve ME, Dragosics B, et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004;53:34-37.
71. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:39-40.
72. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. 2004;10:1088-1094.